Clinical Trials

Papers
(The H4-Index of Clinical Trials is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Stakeholder views about the responsibilities of principal investigators in multicenter randomized controlled trials64
A review of current practice in the design and analysis of extremely small stepped-wedge cluster randomized trials47
Industry payments and brand-name tyrosine kinase inhibitor use amid generic entry43
Treatment selection in multi-arm multi-stage designs: With application to a postpartum haemorrhage trial41
Topic-specific living databases of clinical trials: A scoping review of public databases28
A critique on “A randomized evaluation of on-site monitoring nested in a multinational randomized trial”28
Rethinking intercurrent events in defining estimands for tuberculosis trials24
Dose finding in early-phase human immunodeficiency virus type 1 prevention monoclonal antibody clinical trials23
Landscape of coronavirus disease 2019 clinical trials: New frontiers and challenges23
Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials22
Performance of Cox regression models for composite time-to-event endpoints with component-wise censoring in randomized trials22
Partner engagement for planning and development of non-pharmacological care pathways in the AIM-Back trial21
A Bayesian adaptive design approach for stepped-wedge cluster randomized trials20
Importance of patient engagement in the conduct of pragmatic multicenter randomized controlled trials: The ADAPTABLE experience19
How is missing data handled in cluster randomized controlled trials? A review of trials published in the NIHR Journals Library 1997–202419
Characterization of studies considered and required under Medicare’s coverage with evidence development program19
Training the next generation of clinical trial biostatisticians19
Modeling impact of inflation reduction act price negotiations on new drug pipeline considering differential contributions of large and small biopharmaceutical companies17
Unresolved issues with noninferiority pragmatic trials: Results of a literature survey17
0.14981198310852